Ligand Pharmaceuticals to Acquire XOMA Royalty Company for $740 Million

Ligand Pharmaceuticals Reaches Major Acquisition Agreement

Ligand Pharmaceuticals has officially announced that it has reached an acquisition agreement with biotech royalty investment firm XOMA Royalty Company, with the total transaction value amounting to approximately $740 million. This acquisition marks further consolidation in the biopharmaceutical royalty investment space and has drawn widespread industry attention to AI-driven investment model transformations in the pharmaceutical sector.

Key Transaction Terms

Under the terms of the agreement, Ligand Pharmaceuticals will acquire all outstanding shares of XOMA at a cash price of $39 per share. This price represents a premium of approximately 2.9% over XOMA's closing price of $37.90 last Friday. The transaction is expected to close in the third quarter of 2025.

XOMA Royalty Company is a royalty investment firm focused on the biotech sector. Its core business model involves investing in drug development programs at biopharmaceutical companies to earn future product royalty income. This model has demonstrated stronger value potential in recent years, driven by the wave of AI-assisted drug development.

Industry Context and Strategic Significance

Ligand Pharmaceuticals is itself a major player in the royalty investment space, and the acquisition of XOMA will enable a significant expansion of its biopharmaceutical royalty asset portfolio. The combined company will have a more diversified stream of drug royalty income, covering multiple product pipelines from early clinical stages through commercialization.

Notably, AI technology is currently deeply penetrating every aspect of drug development. From target discovery and molecular design to clinical trial optimization, AI has dramatically shortened new drug development timelines and reduced failure rates. This has led to a reassessment of the pipeline asset values held by royalty investment companies like Ligand and XOMA. Industry analysts have noted that the relatively modest acquisition premium reflects a broad consensus between both parties on the transaction's valuation.

In recent years, merger and acquisition activity in the global pharmaceutical industry has remained robust. Major pharmaceutical companies facing patent cliff pressures have turned to acquisitions to replenish their R&D pipelines. At the same time, the rise of AI-powered pharmaceutical companies has injected new vitality into the royalty investment model, further highlighting the strategic value of related assets.

Future Outlook

Upon completion of this transaction, Ligand Pharmaceuticals is poised to become one of the largest players in the biopharmaceutical royalty investment space. As AI technology continues to deepen its application in drug development, the return certainty of the royalty investment model is expected to improve further.

The market will closely monitor the regulatory approval progress of this transaction, as well as the combined company's specific strategies for integrating assets and optimizing its investment portfolio. For the broader biopharmaceutical investment sector, this deal may usher in a new wave of royalty asset consolidation.